Toboroz
A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
NCT07541170· 3. fázis· Hoffmann-La Roche· Forrás
Még nem toboroz
Study for Evaluating the Safety and Feasibility of Fecal Microbiota Transplant in Stage II-III NSCLC Patients Using ICI Responders as Donors (MIGRANT)
NCT07247786· 2. fázis· Fundación GECP· Forrás
Toboroz
Phase 1/2 multicenter, two-arms, open-label, dose-escalation study of IDP-121 in combination with chemotherapy in patients with relapsed small cell lung cancer (SCLC) (MYCrocytic)
2025-521902-17-00· 1/2. fázis· Idp Discovery Pharma S.L.· Forrás
Még nem toboroz
Optimizing the Use of Aspirin for the Prevention of Preeclampsia
NCT07665853· 3. fázis· Hospital Universitari Vall d'Hebron Research Institute· Forrás
Még nem toboroz
Clinical trial to assess the efficacy and safety of a vaccine for dust mite and Blomia tropicalis allergy.
2025-522773-12-00· 3. fázis· Inmunotek S.L.· Forrás
Toboroz
Study of Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited Stage SCLC Patients
NCT07242547· 2. fázis· Fundación GECP· Forrás
Toboroz
A study to compare Venetoclax Azacitidine and Quizartinib Vs Venetoclax and Azacitidine in newly diagnosed acute myeloid leukemia patient´s ineligible for standard induction chemotherapy
2025-522979-29-00· 3. fázis· Fundacion PETHEMA· Forrás
Toboroz
LY4268989 (MORF-057) Co-Administered with Mirikizumab in Adults with Moderately to Severely Active Ulcerative Colitis: A Phase 2 Study
2025-522338-30-00· 2. fázis· Eli Lilly & Co.· Forrás
Toboroz
A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy
NCT06931717· 3. fázis· ETOP IBCSG Partners Foundation· Forrás
Toboroz
A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008)
2024-518296-56-00· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
A study to evaluate acalabrutinib, in combination with the R-CHOP standard of care, for previously untreated mantle cell lymphoma in Spain.
2025-521152-34-00· 2. fázis· Astrazeneca Farmaceutica Spain S.A.· Forrás
Még nem toboroz
Exploring the Anti-ageing Effects of Metformin in COPD
NCT06999343· 3. fázis· Fundación Instituto de Investigación Sanitaria de Navarra· Forrás
Toboroz
Neoadjuvant Treatment With Atezolizumab and Atezolizumab as Maintenance for the Treatment of Stage III Non Small-Cell Lung Cancer (NSCLC)
NCT07153445· 2. fázis· Fundación GECP· Forrás
Fut, nem toboroz
FARAPULSE Workflow Assessment Registry
NCT06656884· Boston Scientific Corporation· Forrás
Fut, nem toboroz
Study to evaluate the safety and efficacy of a treatment consisting of immunotherapy by subcutaneous injection of a combination of Der p 1/Der p 2/Der p 23 allergens at different doses in patients with allergic rhinitis or rhinoconjunctivitis with or without allergic asthma.
2024-518519-20-01· 2. fázis· Diater Laboratorio De Diagnostico Y Aplicaciones Terapeuticas S.A.· Forrás
Toboroz
Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma
NCT06830759· AbbVie· Forrás
Toboroz
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
NCT06819878· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.
NCT06431633· 3. fázis· Fundación GECP· Forrás
Toboroz
Study of Antitumor Immune Response After cCRT and IO Treatment in Non-resectable III Stage NSCLC Patients
NCT06634199· Fundación GECP· Forrás
Toboroz
A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT06290141· 3. fázis· Sanofi· Forrás
Fut, nem toboroz
A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work
NCT06290128· 3. fázis· Sanofi· Forrás
Toboroz
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
NCT06430801· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
NCT06283966· 3. fázis· AstraZeneca· Forrás
Toboroz
BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT
NCT06059638· Orchestra BioMed, Inc· Forrás
Toboroz
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
NCT06170788· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Fut, nem toboroz
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
NCT06073821· 3. fázis· BeOne Medicines· Forrás
Fut, nem toboroz
Treatment of Functionally Non-significant Vulnerable Plaques in Patients With Multivessel ST-elevation Myocardial Infarction The VULNERABLE Trial
NCT05599061· Fundación EPIC· Forrás
Fut, nem toboroz
AMANTADINE AND TRANSCRANIAL MAGNETIC TRANSCRANIAL MAGNETIC STIMULATION FOR FATIGUE IN MULTIPLE SCLEROSIS: A PHASE III, CONTROLLED, RANDOMISED, DOUBLE-BLIND, CROSSOVER TRIAL
NCT05809414· 3. fázis· Fundacion Para La Investigacion Biomedica Del Hospital Clinico San Carlos· Forrás
Fut, nem toboroz
A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products
NCT05476926· Hoffmann-La Roche· Forrás
Fut, nem toboroz
An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe
NCT05363319· Regeneron Pharmaceuticals· Forrás
Fut, nem toboroz
Extended VRD plus Early Rescue vs Isatuximab-VRD vs Isatuximab-VIberdomide-D for NDMM patients who are candidates for ASCT
2024-517008-12-00· 3. fázis· Fundacion PETHEMA· Forrás
Toboroz
Asciminib Roll-over Study
NCT04877522· 4. fázis· Novartis Pharmaceuticals· Forrás
Toboroz
Intermediate Risk Cervical Cancer: Radical Surgery +/- Adjuvant Radiotherapy
NCT04989647· 3. fázis· The Central and Eastern European Gynecologic Oncology Group· Forrás
Toboroz
Spanish Registry of Patients With IgM Monoclonal Gammopathies
NCT05093153· Fundación Española de Hematología y Hemoterapía· Forrás
Fut, nem toboroz
New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy
NCT04564157· 3. fázis· Fundación GECP· Forrás
Fut, nem toboroz
Personalized Therapy Study - Intrinsic Antitachycardia Pacing Post-Approval Study (iATP PAS)
NCT04496518· Medtronic· Forrás
Fut, nem toboroz
Personalized Therapy Study - HFRS (TriageHF) Post Approval Study
NCT04489225· Medtronic· Forrás
Toboroz
Spanish Registry of Esophagogastric Cancer
NCT04958720· Fundación Sociedad Española de Oncologia Médica· Forrás
Toboroz
International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma
NCT04043494· 3. fázis· University Hospital Muenster· Forrás
Fut, nem toboroz
Study to evaluate the efficacy of 3 different treatments, followed by maintenance treatment, in older adult patients, between 65 and 80 years old, in good general health and newly diagnosed multiple myeloma.
2024-516905-22-00· 3. fázis· Fundacion PETHEMA· Forrás
Fut, nem toboroz
Personalized Therapy Study - Attain Stability Quad Post-Approval Study
NCT04024943· Medtronic· Forrás